about pulmatrix


At Pulmatrix, we are developing innovative inhaled therapies to address serious pulmonary disease using our clinically validated, proprietary iSPERSE technology. Leveraging the unique capabilities of iSPERSE to dramatically advance inhalation technology, we can create new therapies to improve patient outcomes.

Our pipeline of inhaled therapies rrepresents innovative, first-in-class products. Our proprietary pipeline of novel, therapies for respiratory diseases is led by PUR1900, PUR1800 and PUR5700. PUR1900 is an inhaled anti-infective to treat ABPA in severe asthmatics and cystic fibrosis patients. PUR1800 and PUR5700 are novel inhaled anti-inflammatory compounds that selectively inhibit kinases involved in inflammation. PUR1800 is being developed to treat and prevent exacerbations in patients with COPD and PUR5700 is being explored as a therapy for COPD, asthma and IPF. Our pipeline in major pulmonary diseases developed in collaboration with partners is led by PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD).

iSPERSE is a, dry powder technology developed, patented and validated by Pulmatrix scientists and engineers to improve how drugs are directed into the lungs. iSPERSE products are designed to maximize local drug concentrations and reduce systemic side effects, in order to make possible a new generation of inhaled therapies to improve patient outcomes.

© 2018 Pulmatrix, Inc. All Rights Reservedhome   about pulmatrix   platform   pipeline   investors   careers   contact   site design